IJC Heart and Vasculature最新文献

{"title":"Routine stress testing with subsequent coronary angiography versus standard of care in high-risk patients after percutaneous coronary intervention: An updated meta-analysis of randomized controlled trials","authors":"Umar G. Adamu ,&nbsp;David M. Mashilo ,&nbsp;Anupa Patel ,&nbsp;Nqoba Tsabedze","doi":"10.1016/j.ijcha.2025.101681","DOIUrl":"10.1016/j.ijcha.2025.101681","url":null,"abstract":"<div><div>Routine functional stress testing with subsequent coronary angiography is undertaking to detect early restenosis and guide revascularization in high-risk patients after percutaneous coronary intervention (PCI). However, the safety and efficacy of routine functional stress testing over standard care is still debatable. This <em>meta</em>-analysis compares routine functional stress testing vs. standard care in high-risk patients after PCI. We systematically searched PubMed, Embase, and Cochrane Central databases to identify randomized controlled trials (RCTs) that compared functional stress testing versus standard of care after PCI in high-risk patients from inception to January 2025. We calculated the risk ratios (RRs) with 95 % confidence intervals (CIs) using the random-effects model for clinical outcomes. Four RCTs with 6,290 patients, of whom 3,206 (51 %) underwent routine functional stress testing were included in our analyses. The incidence of target lesion revascularization (TLR) was higher in routine functional stress testing (RR: 1.49; 95 % CI: 1.02–2.18;<!--> <!-->p = 0.038) compared with standard care. However, no statistically significant difference was observed for individual outcomes of all-cause mortality (RR: 0.89; 95 % CI: 0.48–1.18;<!--> <!-->p = 0.198), myocardial infarction (MI) (RR: 0.62; 95 % CI: 0.31–1.24;<!--> <!-->p = 0.174), and hospitalization for any cause (RR: 1.22; 95 % CI: 0.24–6.10;<!--> <!-->p = 0.809). The risk of MACE did not significantly differ between the groups (RR: 1.11; 95 % CI: 0.82–1.51; p = 0.480). Routine functional stress testing after PCI in high-risk patients was associated with increased incidence of target lesion revascularization, without reducing the risk of major adverse cardiovascular events.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101681"},"PeriodicalIF":2.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical phenotypes of severe atrial cardiomyopathy and their outcome: A cluster analysis","authors":"R. Ilieva ,&nbsp;P. Kalaydzhiev ,&nbsp;B. Slavchev ,&nbsp;N. Spasova ,&nbsp;E. Kinova ,&nbsp;A. Goudev","doi":"10.1016/j.ijcha.2025.101679","DOIUrl":"10.1016/j.ijcha.2025.101679","url":null,"abstract":"<div><h3>Background</h3><div>Atrial cardiomyopathy (AtCM) encompasses patients with diverse demographics and comorbidities. This study aimed to identify phenotype groups with similar clinical characteristics, compare their mortality and atrial fibrillation (AF) event rates, and assess predictors of mortality.</div></div><div><h3>Methods and Results</h3><div>We performed a hierarchical cluster analysis using Ward’s Method, based on 11 clinical variables. Among 724 consecutive patients with a dilated left atrium (LA), only 196 met the criterion for severe AtCM- defined as a dilated LA with a volume index ≥ 50 ml/m2. We identified 4 clusters: Cluster 1 −younger overweight patients with paroxysmal AF; Cluster 2 −older patients with heart failure (HF) and low BMI; Cluster 3 − diabetic patients with HF; and Cluster 4 − older patients with tachycardia-bradycardia syndrome and implanted pacemakers. Over a median follow-up of 20.6 months, Cluster 2 had the highest mortality rate (29.1 %), followed by Cluster 3 (20.6 %), compared to Clusters 1 and 4 (11.4 % and 10.8 %, respectively, p = 0.045). For AF events, Cluster 1 had the highest incidence (37 %), followed by Cluster 3 (35 %), Cluster 2 (24 %), and Cluster 4 (19 %, p = 0.309). Heart failure (HR 4.4, CI 1.5–12.7, p = 0.006), cancer (HR 3.3, CI 1.6–6.9, p = 0.002), and severe tricuspid regurgitation (HR 5.4, CI 2.6–11.3, p &lt; 0.001) were predictors of poor outcomes.</div></div><div><h3>Conclusion</h3><div>In severe AtCM patients, four clusters were identified, each with unique comorbidities and mortality rates but similar AF event rates. Clinical and echocardiographic factors were linked to higher mortality risk.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101679"},"PeriodicalIF":2.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based measurement of cardiothoracic ratio in chest X-rays and prediction of echocardiographic congestive heart failure","authors":"Joshua Ra ,&nbsp;Heejun Shin ,&nbsp;Christopher Park ,&nbsp;Yong-Xiang Wang ,&nbsp;Dongmyung Shin","doi":"10.1016/j.ijcha.2025.101678","DOIUrl":"10.1016/j.ijcha.2025.101678","url":null,"abstract":"<div><h3>Background</h3><div>This study presents an artificial intelligence (AI) model for automated cardiothoracic ratio (CTR) measurement from chest X-rays (CXRs) and evaluates its association with severe left ventricular hypertrophy (SLVH) and dilated left ventricle (DLV) diagnosed by echocardiography. The study also assesses CTR’s prognostic value for predicting future SLVH/DLV development.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, an AI algorithm measured CTR on 71,129 CXRs from 24,673 patients from 2013 to 2018 in the CheXchoNet database. SLVH/DLV was defined using echocardiographic criteria. Diagnostic accuracy was assessed using AUROC and AUPRC alongside sensitivity and specificity at various CTR thresholds. Logistic regression was performed for CXR-echocardiogram pairs. Time-to-event analysis was performed on 9,890 patients without baseline SLVH/DLV.</div></div><div><h3>Results</h3><div>Among 24,673 patients (mean age: 62.1 years; female sex: 56.9 %), mean CTR was higher in SLVH/DLV patients (0.56 ± 0.07) than those without (0.52 ± 0.07; p &lt; 0.001). AUROC was 0.70 (95 % CI: 0.69–0.70). At a CTR threshold of 0.53, sensitivity was 70 % and specificity 60 %. Increased CTR was associated with SLVH/DLV risk on paired echocardiogram, with an odds ratio of 1.26 at a CTR of 0.65 compared to CTR at 0.50 (95 % CI: 1.24–1.27, p &lt; 0.001). Time-to-event analysis on patients without baseline SLVH/DLV showed patients with baseline CTR &gt; 0.65 had a 4.13-fold increased risk of developing SLVH/DLV in the future compared to patients with CTR ≤ 0.50 (adjusted HR: 4.13; 95 % CI: 2.48–6.89; p &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>AI-based CTR measurement helps predict SLVH/DLV and could be used for risk stratification for cardiovascular care.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101678"},"PeriodicalIF":2.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143807512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of myocardial flow reserve by PET imaging in patients with suspected coronary artery disease: A systematic review and meta-analysis","authors":"Adriana D’Antonio ,&nbsp;Roberta Assante ,&nbsp;Emilia Zampella ,&nbsp;Valeria Cantoni ,&nbsp;Roberta Green ,&nbsp;Valeria Gaudieri ,&nbsp;Teresa Mannarino ,&nbsp;Maria Falzarano ,&nbsp;Federica Volpicelli ,&nbsp;Paolo Cutillo ,&nbsp;Francesca Matrisciano ,&nbsp;Pietro Buongiorno ,&nbsp;Mariarosaria Panico ,&nbsp;Carmela Nappi ,&nbsp;Domenico Cozzolino ,&nbsp;Mario Petretta ,&nbsp;Alberto Cuocolo ,&nbsp;Wanda Acampa","doi":"10.1016/j.ijcha.2025.101677","DOIUrl":"10.1016/j.ijcha.2025.101677","url":null,"abstract":"<div><h3>Purpose</h3><div>We performed a systematic review and <em>meta</em>-analysis of published studies evaluating the value of myocardial flow reserve (MFR) assessed by positron emission tomography (PET) imaging in predicting adverse cardiovascular events in patients with suspected coronary artery disease (CAD).</div></div><div><h3>Material and methods</h3><div>Studies published until December 2024 were identified by database search. We included studies evaluating MFR by PET imaging with data on adjusted hazard ratio (HR) for the occurrence of adverse cardiovascular events.</div></div><div><h3>Results</h3><div>We identified 8 eligible articles including 12.087 patients with a mean follow-up of 2.98 ± 0.69 years. The pooled HR for the occurrence of events was 2.19 (95 % CI 1.80–2.68) and no heterogeneity was observed. The pooled incidence rate ratio (IRR) was 3.26 (95 % CI 2.43–4.37) and the heterogeneity was 37.7 %. At <em>meta</em>-regression analysis no significant association was found between HR for adverse events and demographic and clinical variables considered.</div></div><div><h3>Conclusion</h3><div>MFR assessed by PET imaging is a valuable noninvasive prognostic indicator in the evaluation of patients with suspected CAD.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101677"},"PeriodicalIF":2.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study","authors":"Yehua Tang ,&nbsp;Jianling Fan ,&nbsp;Xingyun Hou ,&nbsp;Honghong Wu ,&nbsp;Jiaqi Zhang ,&nbsp;Jia Wu ,&nbsp;Yifan Wang ,&nbsp;Zhiyu Zhang ,&nbsp;Bin Lu ,&nbsp;Jiaoyang Zheng","doi":"10.1016/j.ijcha.2025.101676","DOIUrl":"10.1016/j.ijcha.2025.101676","url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests a link between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiac arrhythmia. This study aims to investigate the potential relationship between MASLD and atrial fibrillation (AF).</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 8511 participants (age &gt; 65 years) without a history of cardiovascular diseases, cancer, or severe kidney dysfunction. MASLD was diagnosed using hepatic ultrasound in the presence of at least one cardiometabolic risk factor. Poisson regression models were employed to estimate the relative risk (RR) of AF, adjusting for potential confounders.</div></div><div><h3>Results</h3><div>Participants were categorized into MASLD (n = 3,926) and non-MASLD (n = 4,585) groups. During a mean follow-up period of 3.65 ± 1.20 years, 307 participants with MASLD developed AF, however, the number in the non-MASLD group was 144 (incidence rate 7.82 % vs. 3.14 %). After adjusting for multiple cardiovascular risk factors, MASLD was associated with increased risk of AF (RR = 1.55, 95 %, confidence interval (CI): 1.12–2.13). Positive correlations were observed between age, body mass index (BMI), systolic and diastolic blood pressure, low-density lipoprotein levels, and AF risk. Subgroup analysis revealed a stronger association between MASLD and AF in participants with BMI &lt; 24 kg/m² (P &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>This study highlights a significant association between MASLD and an increased risk of developing AF. The elevated risk in patients with MASLD may involve mechanisms extending beyond traditional cardiometabolic factors, particularly in individuals with lower BMI. Further experimental research is warranted to elucidate the underlying pathways linking MASLD and AF.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101676"},"PeriodicalIF":2.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic inflammation-based Glasgow Prognostic Score as a prognostic indicator in chronic heart failure","authors":"Shigeto Namiuchi ,&nbsp;Kotaro Nochioka ,&nbsp;Ryoichi Ushigome ,&nbsp;Shinichiro Sunamura ,&nbsp;Atsushi Tanita ,&nbsp;Tsuyoshi Ogata ,&nbsp;Kazuki Noda ,&nbsp;Toru Takii ,&nbsp;Hiroaki Shimokawa ,&nbsp;Satoshi Yasuda ,&nbsp;on behalf of the CHART-2 Investigators","doi":"10.1016/j.ijcha.2025.101660","DOIUrl":"10.1016/j.ijcha.2025.101660","url":null,"abstract":"<div><h3>Background</h3><div>The Glasgow Prognostic Score (GPS), based on C-reactive protein and serum albumin concentrations provides useful prognostic information for patients with cancer or acute decompensated heart failure (HF). Herein, we aimed to evaluate the relationship between the GPS and long-term prognosis in patients with chronic HF.</div></div><div><h3>Methods</h3><div>In this large multicentre prospective observational study, part of the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) Study, we analysed the relationship between mortality and the GPS in 6,480 patients with chronic HF (mean age, 68 ± 13 years; 69 % male). Patients with elevated C-reactive protein levels (&gt;1.0 mg/dL) and hypoalbuminaemia (&lt;3.5 g/dL) received a GPS of 2; those with either received a GPS of 1, and those with neither received a GPS of 0.</div></div><div><h3>Results</h3><div>During median follow-up of 9.62 years, 2,564 patients (39.6 %) died. Increased GPS was associated with a significantly higher mortality risk in Kaplan–Meier analysis (log-rank P &lt; 0.0001). This trend was consistent across sex, age, New York Heart Association class, HF stage and type, and cancer history. Adjusted Cox proportional hazards analysis showed the following hazard ratios for all-cause death, relative to a GPS of 0, 1.27 (95 % confidence interval, 1.13–1.44; P &lt; 0.0001) for a GPS of 1 and 1.83 (95 % confidence interval, 1.45–2.32; P &lt; 0.0001) for a GPS of 2. This increased risk was independent of B-type natriuretic peptide levels.</div></div><div><h3>Conclusions</h3><div>The GPS, which reflects systemic inflammation status, is a useful predictor of long-term prognosis in patients with chronic HF.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101660"},"PeriodicalIF":2.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential","authors":"Rongli Wang ,&nbsp;Yi He ,&nbsp;Yan Wang ,&nbsp;Jing Wang ,&nbsp;Hu Ding","doi":"10.1016/j.ijcha.2025.101675","DOIUrl":"10.1016/j.ijcha.2025.101675","url":null,"abstract":"<div><div>Cardiovascular disease is one of the leading causes of mortality worldwide, and involves complex pathophysiological mechanisms that encompass various biological processes and molecular pathways. Post-translational modifications of proteins play crucial roles in the occurrence and progression of cardiovascular diseases, among which palmitoylation is particularly important. Various proteins associated with cardiovascular diseases can be palmitoylated to enhance the hydrophobicity of their molecular subdomains. This lipidation can significantly affect some pathophysiological processes, such as metabolism, inflammation by altering protein stability, localization, and signal transduction. In this review, we narratively summarize recent advances in the palmitoylation of proteins related to cardiovascular diseases and discuss its potential as a therapeutic target.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101675"},"PeriodicalIF":2.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-test probability estimation of coronary artery disease can be improved by adding an acoustic-based risk score","authors":"Louise H Bjerking ,&nbsp;Samuel E Schmidt ,&nbsp;Kim W Skak-Hansen ,&nbsp;Simon Winther ,&nbsp;Morten Böttcher ,&nbsp;Søren Galatius ,&nbsp;Eva Prescott","doi":"10.1016/j.ijcha.2025.101672","DOIUrl":"10.1016/j.ijcha.2025.101672","url":null,"abstract":"<div><h3>Background</h3><div>The American Heart Association/American College of Cardiology (AHA/ACC) 2021 Chest Pain Guidelines introduced a new pre-test probability (PTP) model for obstructive coronary artery disease (CAD). The model recommends a 15 % risk cut-off for referral for further testing. Whether addition of a risk score measured from acoustic detection of coronary turbulence obtained by the noninvasive device CADScor®System (CAD-score) improves the AHA/ACC-PTP capability to assign the correct risk category has not been tested.</div></div><div><h3>Methods</h3><div>Patients with symptoms suggestive of CAD referred for coronary CT angiography and undergoing a same-day CAD-score were included. PTP was calculated based on sex, age, and symptoms. All patients with suspected stenosis on CT angiography were referred for invasive angiography. A CAD-score ≤ 20 was used as cut-off for low likelihood of CAD.</div></div><div><h3>Results</h3><div>The study population consisted of 2874 patients (47 % women, median age [IQR] 58 [52–65] years). PTP categorized 2044 (71 %) of patients as &gt; 15 % amongst whom 387 (18.9 %) were re-classified to low likelihood by a CAD-score ≤ 20. In patients aged &lt; 70 without hypertension, 37 % were re-classified to low probability. Of the 830 patients with low PTP ≤ 15 %, 68.7 % had a CAD-score ≤ 20 indicating a deferred testing strategy.</div></div><div><h3>Conclusion</h3><div>Adding an acoustic-based CAD-score to the PTP in patients with AHA/ACC defined-PTP &gt; 15 % risk can reduce the number of diagnostic tests by overall 19 %, and 37 % in subgroups, and may support cost-effective clinical decision-making. Moreover, CAD-score may aid risk stratification in patients, particularly with AHA/ACC-PTP ≤ 15 %.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101672"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulsed field ablation using a circular electrode array catheter in patients with atrial fibrillation: A workflow optimization study evaluating the role of mapping","authors":"Melanie A. Gunawardene ,&nbsp;Jens Hartmann ,&nbsp;Jannis Dickow ,&nbsp;Rahin Wahedi ,&nbsp;Tim Harloff ,&nbsp;Johanna Jezuit ,&nbsp;Eike P. Tigges ,&nbsp;Mario Jularic ,&nbsp;Borislav Dinov ,&nbsp;Nele Gessler ,&nbsp;Stephan Willems","doi":"10.1016/j.ijcha.2025.101674","DOIUrl":"10.1016/j.ijcha.2025.101674","url":null,"abstract":"<div><h3>Background</h3><div>Pulsed field ablation (PFA) with a circular-electrode-array catheter (cPFA) has shown to be effective and safe. However, data on procedural workflow are limited.</div></div><div><h3>Objective</h3><div>to analyze the process of streamlining cPFA-procedures including evaluation of fluoroscopy versus 3D-map guidance and lesion characteristics.</div></div><div><h3>Methods</h3><div>Consecutive AF-patients underwent cPFA-based pulmonary vein isolation (PVI) in three phases (learning-phase-I: visualization of cPFA in 3D-map; phase-II: operator blinded to 3D-map with fluoroscopy-guidance only; phase-III: optimized mapping and ablation). Additionally, hemolysis-parameters were collected.</div></div><div><h3>Results</h3><div>A total of 35 patients (57 % paroxysmal-AF, age 63.4 ± 9.4 years) were enrolled: n = 10 phase-I, n = 15 phase-II, n = 10 in phase III. Total procedure and fluoroscopy time was 51.9 ± 9.4 and 6.7 ± 3.1 min, respectively. First-pass PFA isolation-rate was lowest in the fluoroscopy-only phase-II (I:86 %, II:81 %, III:100 %, p = 0.0079). Insufficient PV ablation with remaining conduction occurred mostly anterior (n = 8/15, 53 %) and at the carina (n = 4/15; 27 %). Following additional PFA, all 142 PVs (100 %) were acutely isolated.</div><div>Procedure times between phase II and III did not differ (49 ± 8 vs. 46 ± 3 mins p = 0.23). Fluoroscopy times were longer in phase-II (phase-I: 5.8 ± 1.3, phase-II: 9.2 ± 2.9, phase-III: 3.8 ± 1.0 mins, p &lt; 0.0001). No complications occurred. Pre- and post-ablation hemoglobin (14.4 ± 1.4 vs. 13.5 ± 1.2 g/dl, p = 0.0169) and LDH (188 ± 39 vs. 210 ± 29 U/l, p = 0.0007) were different.</div></div><div><h3>Conclusion</h3><div>The cPFA-catheter allows for fast and efficient PVI. A fluoroscopy-only approach creates distal PV ablation lesions that are associated with residual PV conduction along the carina and anterior antrum. However, with visualization and mapping, creation of wide antral ablation lesions is feasible without prolonging procedural duration.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101674"},"PeriodicalIF":2.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes and atrial fibrillation: Causality is still a black-box","authors":"Florian Bruns,&nbsp;Dobromir Dobrev,&nbsp;Anke Fender","doi":"10.1016/j.ijcha.2025.101669","DOIUrl":"10.1016/j.ijcha.2025.101669","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"58 ","pages":"Article 101669"},"PeriodicalIF":2.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}